Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
Rachna T. Shroff(University of Arizona), Mitesh J. Borad(Jacksonville College), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Milind Javle(The University of Texas MD Anderson Cancer Center), Michiko Iwasaki(Loyola University Maryland), Peter Masci(Mayo Clinic Hospital), Daniel H. Ahn(Mayo Clinic Hospital), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Tanios Bekaii‐Saab(WinnMed), Ramesh K. Ramanathan(Ironwood Pharmaceuticals (United States)), Gauri R. Varadhachary(The University of Texas MD Anderson Cancer Center)
Cited by 472
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k